MedCity News February 27, 2025
Zevra Therapeutics received a priority review voucher for Miplyffa, the first FDA-approved treatment for the rare metabolic disorder Niemann Pick disease type C. Though Zevra has other drug candidates that could benefit from the voucher, the biotech is selling it to an undisclosed buyer.
Zevra Therapeutics is still ramping up sales of its new FDA-approved drug, but the company has already found a way to cash in big on this therapy for a rare metabolic disorder. The priority review voucher awarded alongside the approval of Miplyffa will be sold for $150 million, Zevra announced Thursday.
The buyer of the voucher was not disclosed. Celebration, Florida-based Zevra said it expects the transaction will close within 30 to 45 days.
Today's Sponsors
Today's Sponsor